; The Vaccine and Cell Therapy Core Laboratory is a highly specialized shared resource at the NYU Cancer Institute (NYUCI) that is an essential part of the Tumor Vaccine Program. The purpose of the laboratory is to support clinical trials of experimental immunotherapies for cancer and chronic viral infections such as HIV/AIDS at NYU Medical Center and at collaborating institutions. The laboratory provides two types of services to meet this purpose. First, the laboratory prepares vaccines and cellular immunotherapies in a dedicated, controlled space in accordance with current Good Manufacturing Practice (cGMP) regulations as required by the US Food and Drug Administration (FDA). This cGMP laboratory features three class 10,000 (ISO 7) cleanrooms, and has been designed with the flexibility to manufacture virtually any type of therapy that uses manipulated human cells. It is one of only a handful of such laboratories in the Greater New York metropolitan region. Second, the laboratory also features a very well equipped Immunology Laboratory that offers a variety of sophisticated immune monitoring technologies and services to measure patients'responses to vaccination. Access to this facility has enabled investigators at NYU to undertake investigator initiated studies as well as take part in pharmaceutical-sponsored studies, thus providing patients at the Clinical Cancer Center access to novel therapies in a number of disease settings. Since opening in early 2006, the facility has supported 20 completed and ongoing immunotherapy trials for cancer at NYU, 2 HIV vaccine trials at Massachusetts General Hospital, and immune monitoring contracted by Merck. The user base for the laboratory continues to expand as more investigators take advantage of this remarkable resource.

Public Health Relevance

The Vaccine and Cell Therapy Core Laboratory serves an important role in translating promising laboratory results into novel therapies by providing a dedicated facility for the manufacturing of immunotherapies and testing their effectiveness in vaccinated patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-33
Application #
8436450
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
33
Fiscal Year
2013
Total Cost
$71,259
Indirect Cost
$29,218
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Wadghiri, Youssef Z; Hoang, Dung Minh; Leporati, Anita et al. (2018) High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. Sci Rep 8:7687
Khodadadi-Jamayran, Alireza; Akgol-Oksuz, Betul; Afanasyeva, Yelena et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9:12868-12878
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:

Showing the most recent 10 out of 1170 publications